HK1214148A1 - 用於治疗中枢介导的恶心及呕吐的组合物及方法 - Google Patents

用於治疗中枢介导的恶心及呕吐的组合物及方法 Download PDF

Info

Publication number
HK1214148A1
HK1214148A1 HK16102110.3A HK16102110A HK1214148A1 HK 1214148 A1 HK1214148 A1 HK 1214148A1 HK 16102110 A HK16102110 A HK 16102110A HK 1214148 A1 HK1214148 A1 HK 1214148A1
Authority
HK
Hong Kong
Prior art keywords
netupitant
palonosetron
nausea
dosage form
vomiting
Prior art date
Application number
HK16102110.3A
Other languages
English (en)
Chinese (zh)
Inventor
‧特蘭托
F‧特兰托
‧坎托雷吉
S‧坎托雷吉
‧羅西
G‧罗西
‧坎內拉
R‧坎内拉
‧邦那迪奧
D‧邦那迪奥
‧布拉利亞
R‧布拉利亚
Original Assignee
赫尔森保健股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1214148(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 赫尔森保健股份公司 filed Critical 赫尔森保健股份公司
Publication of HK1214148A1 publication Critical patent/HK1214148A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
HK16102110.3A 2009-11-18 2016-02-24 用於治疗中枢介导的恶心及呕吐的组合物及方法 HK1214148A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US61/262,470 2009-11-18
US38270910P 2010-09-14 2010-09-14
US61/382,709 2010-09-14

Publications (1)

Publication Number Publication Date
HK1214148A1 true HK1214148A1 (zh) 2016-07-22

Family

ID=43608757

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102110.3A HK1214148A1 (zh) 2009-11-18 2016-02-24 用於治疗中枢介导的恶心及呕吐的组合物及方法
HK16102109.6A HK1214147A1 (zh) 2009-11-18 2016-02-24 用於治疗中枢介导的恶心及呕吐的组合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102109.6A HK1214147A1 (zh) 2009-11-18 2016-02-24 用於治疗中枢介导的恶心及呕吐的组合物及方法

Country Status (40)

Country Link
US (1) US12042494B2 (enExample)
EP (3) EP2727590B1 (enExample)
JP (1) JP5890780B2 (enExample)
KR (1) KR101615108B1 (enExample)
CN (6) CN104856998A (enExample)
AP (1) AP3083A (enExample)
AU (1) AU2010320598B2 (enExample)
BR (1) BR112012011485B1 (enExample)
CA (1) CA2778301C (enExample)
CL (1) CL2012001276A1 (enExample)
CO (1) CO6551693A2 (enExample)
CR (1) CR20120216A (enExample)
CU (1) CU24048B1 (enExample)
CY (1) CY1118062T1 (enExample)
DK (2) DK2722045T3 (enExample)
DO (1) DOP2012000138A (enExample)
EA (1) EA026815B1 (enExample)
EC (1) ECSP12011907A (enExample)
ES (4) ES2623503T3 (enExample)
GE (1) GEP20156226B (enExample)
GT (1) GT201200156A (enExample)
HK (2) HK1214148A1 (enExample)
HR (3) HRP20140759T1 (enExample)
HU (1) HUE029677T2 (enExample)
IL (1) IL219576A (enExample)
LT (1) LT2722045T (enExample)
MA (1) MA33810B1 (enExample)
MX (1) MX2012005347A (enExample)
MY (1) MY159393A (enExample)
NI (1) NI201200090A (enExample)
NZ (1) NZ599439A (enExample)
PE (1) PE20121483A1 (enExample)
PH (1) PH12012500887A1 (enExample)
PL (3) PL2361090T3 (enExample)
PT (2) PT2722045T (enExample)
RS (2) RS53491B1 (enExample)
SI (2) SI2722045T1 (enExample)
SM (1) SMT201400112B (enExample)
TN (1) TN2012000170A1 (enExample)
WO (1) WO2011061622A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
ES2672099T3 (es) * 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
JP2014530249A (ja) * 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
BR112017018620A2 (pt) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. método de administração de tradipitanto, e, tradipitanto.
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
WO2019148247A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Oral formulations and uses thereof
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
IL321446A (en) 2022-12-12 2025-08-01 Tiefenbacher Alfred E Gmbh & Co Kg Fixed-dose combination including netopitant and flunosterone
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0430190T3 (da) 1989-11-28 1995-08-21 Syntex Inc Hidtil ukendte tricykliske forbindelser
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
ATE400556T1 (de) 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
AU1608502A (en) 2000-12-14 2002-06-24 Hoffmann La Roche Self emulsifying lipid matrix (selm)
JP5690461B2 (ja) 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EA200801738A1 (ru) * 2006-02-23 2008-12-30 Пфайзер Лимитед Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
ES2325339T3 (es) * 2006-10-24 2009-09-01 Helsinn Healthcare S.A. Capsulas blandas que comprenden hidrocloruro de palonosetron que tienen una estabilidad y una biodisponibilidad mejoradas.
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
EP2247757A2 (en) * 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente

Also Published As

Publication number Publication date
US12042494B2 (en) 2024-07-23
PL2361090T3 (pl) 2014-10-31
WO2011061622A1 (en) 2011-05-26
CN104856999A (zh) 2015-08-26
US20230263799A1 (en) 2023-08-24
CO6551693A2 (es) 2012-10-31
BR112012011485A2 (pt) 2018-04-03
PH12012500887A1 (en) 2016-08-26
NI201200090A (es) 2012-11-13
CN106421793B (zh) 2023-06-16
EA201290356A1 (ru) 2012-12-28
CA2778301A1 (en) 2011-05-26
GT201200156A (es) 2014-03-27
CL2012001276A1 (es) 2012-12-07
CU24048B1 (es) 2014-12-26
CN106421793A (zh) 2017-02-22
RS53491B1 (sr) 2015-02-27
ES2559475T3 (es) 2016-02-12
PE20121483A1 (es) 2012-12-02
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
GEP20156226B (en) 2015-01-26
CN107050455A (zh) 2017-08-18
NZ599439A (en) 2014-06-27
TN2012000170A1 (en) 2013-12-12
SI2722045T1 (sl) 2017-02-28
BR112012011485B1 (pt) 2021-06-29
CY1118062T1 (el) 2017-06-28
DOP2012000138A (es) 2012-11-15
DK2361090T3 (da) 2014-08-25
PL2722045T3 (pl) 2017-03-31
PT2722045T (pt) 2016-10-18
MX2012005347A (es) 2012-08-03
HUE029677T2 (hu) 2017-03-28
CU20120078A7 (es) 2012-10-15
CN104856998A (zh) 2015-08-26
CN107050455B (zh) 2020-09-29
EP2727590B1 (en) 2015-10-21
HRP20161277T1 (hr) 2016-11-18
HRP20140759T1 (hr) 2014-10-24
CR20120216A (es) 2012-07-24
EP2722044B1 (en) 2017-01-04
IL219576A (en) 2017-08-31
EP2727590A1 (en) 2014-05-07
AU2010320598B2 (en) 2016-06-16
JP2013511507A (ja) 2013-04-04
SI2361090T1 (sl) 2014-09-30
KR101615108B1 (ko) 2016-05-12
HRP20170419T1 (hr) 2017-06-02
EA026815B1 (ru) 2017-05-31
SMT201400112B (it) 2014-11-10
PL2722044T3 (pl) 2017-08-31
MA33810B1 (fr) 2012-12-03
ES2595077T3 (es) 2016-12-27
AU2010320598A1 (en) 2012-06-14
MY159393A (en) 2016-12-30
EP2361090B1 (en) 2014-05-21
LT2722045T (lt) 2016-09-26
CA2778301C (en) 2016-06-14
HK1214147A1 (zh) 2016-07-22
CN106512010A (zh) 2017-03-22
JP5890780B2 (ja) 2016-03-22
ES2494015T3 (es) 2014-09-12
ECSP12011907A (es) 2012-10-30
RS55206B1 (sr) 2017-01-31
AP2012006278A0 (en) 2012-06-30
AP3083A (en) 2015-01-31
IL219576A0 (en) 2012-06-28
ES2623503T3 (es) 2017-07-11
DK2722045T3 (en) 2016-10-24
KR20120101456A (ko) 2012-09-13
CN102655864A (zh) 2012-09-05
PT2361090E (pt) 2014-09-03

Similar Documents

Publication Publication Date Title
US12042494B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
US11559523B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1228787A1 (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1171391A (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1228787B (en) Compositions and methods for treating centrally mediated nausea and vomiting